ADVERTISEMENT
Log in here to read the desired article.
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 283 entries already.
Individually customised therapies for every patient this is the vision of the future which numerous companies, research institutions, and clusters focusing on precision medicine in Saxony are working along the entire value creation chain. They are primarily active in oncology and have gained national and international acclaim and renown both in highly specialised cancer diagnostics and innovative treatment methods.
Biotechnology is helping us tackle challenges such as emerging diseases, the impact of ageing in healthcare, population growth, climate change, and the green transition of the economy. Precision medicines, advanced therapies, mRNA and gene editing technologies are transforming the way diseases can be diagnosed and treated, providing life-saving solutions. Biotechnology is also at the forefront of building a sustainable economy, developing better crops, providing new protein sources, and producing bio-based materials.
London-based Engitix Ltd has appointed a new Chief Scientific Officer (CSO). Christopher Stevenson, Ph.D. took over the position at the beginning of September.
Eva Schlintl joined the LISAvienna team at the beginning of September. Most recently, she managed the LISA Life Science Austria programme of Austria Wirtschaftsservice Gesellschaft mbH (aws).
NorthX Biologics AB has appointed Dr Janet Hoogstraate as its new Chief Executive Officer, effective at the end of August.
Basel- and Heidelberg-based CDMO Celonic Group has appointed Dr Samanta Cimitan as Chief Executive Officer (CEO).
ViroCell Biologics, based in London, Dublin and New York, has appointed Brian Collins as Chief Financials Officer.
Toulouse-based Flash Therapeutics has appointed Jerome Bedier as its new President.
The Innovative Health Initiative (IHI) Governing Board has appointed Niklas Blomberg to be the next Executive Director of the organisation. Dr Blomberg has extensive experience of working in Europe’s life science sector, and is currently Director of ELIXIR, the European life sciences data infrastructure. He will take up his duties at IHI in early 2024.